Browse the evidence

Early Time-Restricted Eating (eTRE) offers specific cardiometabolic benefits (glucose tolerance, insulin sensitivity) independent of weight loss, though practical adherence is low.

If you want metabolic health benefits, try finishing your last meal by 3 PM. However, be aware this is socially difficult and may not be sustainable long-term. If you can't do it, standard timing with good food quality is better than quitting.

Retatrutide, a triple GLP-1/GCGR/GIP receptor agonist, produces significant weight loss (-22.1% placebo-subtracted) in individuals with obesity.

Retatrutide is an emerging triple-agonist injection that targets GLP-1, GCGR, and GIP receptors to produce significant weight loss. It is currently in phase II trials, so long-term safety data is not yet fully established, but early results show high efficacy.

Tirzepatide produces clinically significant reductions in HbA1c and body weight in real-world type 2 diabetes patients, with greater efficacy observed in GLP-1 receptor agonist-naïve patients compared to those switched from prior GLP-1 therapy.

For patients with Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection for lowering blood sugar and losing weight. While real-world results are slightly less dramatic than clinical trials, they are still clinically significant. Patients who have never used GLP-1 agonists before tend to see the best results, but those switching from other GLP-1 drugs also benefit from improved A1C and weight loss.

Chickpeas stimulate satiety hormones (GLP-1, PYY) and reduce appetite, though meta-analysis of insulin response is inconsistent.

Use chickpeas to help manage hunger. They trigger satiety hormones like PYY and GLP-1. If you are sensitive to fiber, try chickpea flour or puree rather than whole beans to improve digestibility.

Weight loss achieved through GLP-1 agonists or lifestyle interventions improves the severity and treatment response of immune-mediated skin diseases like psoriasis and hidradenitis suppurativa.

If you have psoriasis or hidradenitis suppurativa, losing weight can directly reduce the severity of your skin lesions and improve how well your treatments work. This is because excess fat tissue drives inflammation. Managing your weight helps calm the underlying immune response.

Adding DPP4 inhibitors (e.g., sitagliptin) to metformin significantly improves glycemic profiles (fasting blood sugar and HOMA-IR) in women with PCOS compared to metformin alone.

If metformin alone isn't controlling your blood sugar or insulin resistance, adding a DPP4 inhibitor (like sitagliptin) is a clinically supported next step. This combination targets glucose metabolism more effectively than metformin alone in PCOS patients.

Adding Thiazolidinediones (TZDs) to metformin has the most significant influence on lipid levels (specifically lowering LDL and improving lipid profiles) in women with PCOS.

If lipid management is a primary concern in your PCOS treatment, adding a TZD (like pioglitazone) to metformin is the most effective strategy among the reviewed drugs for improving your lipid profile.

Efpeglenatide, a long-acting GLP-1 receptor agonist administered once weekly or every two weeks, significantly reduces body weight and improves glycemic control (reverting pre-diabetes to normoglycemia) in patients with obesity or overweight without type 2 diabetes, regardless of baseline BMI, age, or pre-diabetes status.

If you have obesity or are overweight with health issues but no diabetes, efpeglenatide is a once-weekly (or bi-weekly) injection that can help you lose weight and improve your blood sugar control. It works regardless of your age or how much you weigh. You should also try to eat about 500 fewer calories a day and be more physically active. Common side effects are stomach-related, like nausea, but these often get better over time.

Bariatric surgery and incretin-based therapies (GLP-1 RAs, tirzepatide) reduce pancreatic disease burden and improve metabolic profiles relevant to pancreatic pathology.

If you are considering weight loss medications like GLP-1 agonists (e.g., semaglutide) or dual agonists (e.g., tirzepatide), current evidence suggests they do not increase the risk of pancreatitis or pancreatic cancer. They may actually help reduce pancreatic inflammation and disease burden by improving metabolic health.

Semaglutide (SEM) is the most popularly searched GLP-1 receptor agonist for weight loss, yet it exhibits the lowest proportion of severe adverse drug reactions (ADRs) compared to other GLP-1 RAs, despite having the highest absolute number of spontaneous safety reports.

Semaglutide is the most searched GLP-1 for weight loss, leading to high prescription volumes and consequently the highest number of adverse event reports. However, data shows it actually has the lowest rate of severe adverse reactions compared to other GLP-1 drugs. The high volume of reports is likely due to its popularity and off-label use driven by social media, rather than inherent high severity. Users should be aware that off-label use increases risks like overdose and should be monitored by a healthcare professional.

A significant proportion of patients subscribe to digital weight-loss services primarily to access GLP-1 receptor agonist (GLP-1 RA) medications after failing stand-alone lifestyle interventions, supporting the critique that some DWLSs function primarily as medication access pathways.

If you have tried diet and exercise without success, you are not alone. Digital services that offer GLP-1 medications may be a viable option, but ensure they provide medical supervision and are not just a direct-to-consumer pharmacy.

Weight loss interventions (pharmacological or bariatric) in sarcopenic obesity can improve muscle-specific strength and functional parameters despite absolute muscle mass loss, potentially reversing the sarcopenic obesity diagnosis.

If you are considering weight loss medication for obesity, discuss the potential benefits for muscle function. Even if you lose some muscle mass, your strength and ability to function may improve due to reduced fat in muscles and better metabolism. This can reverse sarcopenic obesity.

Treatment with GLP-1 receptor agonists (semaglutide or dulaglutide) significantly reduces biochemical markers of liver fibrosis (FIB-4 score) and inflammation (De Ritis ratio) in patients with type 2 diabetes and MASLD over 180 days.

For patients with Type 2 Diabetes and fatty liver disease, GLP-1 agonists like semaglutide or dulaglutide (taken weekly) can significantly improve liver health markers (specifically fibrosis risk scores) over 6 months, even without changes to diet or exercise. This suggests these drugs offer liver-specific benefits beyond just weight loss or blood sugar control.

Once-weekly subcutaneous semaglutide (1 mg) produces clinically significant weight loss (median 4.4% in diabetics, 3.4% in non-diabetics) and improves glycemic control (HbA1c reduction of 0.4%) in patients with type 2 diabetes over 6 months.

If you have Type 2 Diabetes, once-weekly semaglutide (starting at 0.25mg and titrating up to 1mg) is a proven tool for losing weight (average ~4-5%) and improving blood sugar control. It works by mimicking a gut hormone to slow digestion and regulate insulin. While nausea is common, it is usually mild. It is not a magic bullet; you still need to eat a balanced diet, but the drug significantly aids the process.

Semaglutide (1 mg) promotes significant weight loss and improves BMI in patients without Type 2 Diabetes, without causing significant changes in HbA1c or hypoglycemia risk.

If you do not have diabetes but struggle with weight, semaglutide (1 mg weekly) can help you lose about 3-4% of your body weight. Because it works based on blood sugar levels, it does not typically cause dangerous low blood sugar (hypoglycemia) in non-diabetics. It is used off-label for this purpose but is supported by clinical guidelines.

Semaglutide improves cardiometabolic risk factors, including diastolic blood pressure, in patients without diabetes, while maintaining renal stability in both diabetic and non-diabetic populations.

Semaglutide offers cardiovascular benefits beyond weight loss, such as lowering diastolic blood pressure in non-diabetics. It also appears to protect kidney function (stable creatinine and albumin/creatinine ratio) in both diabetic and non-diabetic patients, making it a favorable option for those with cardiometabolic risks.

High dietary protein intake is not detrimental to bone health and may support bone microarchitecture and strength, particularly from animal and dairy sources.

You do not need to limit protein for the sake of your bones. High protein intake, especially from dairy and animal sources, is associated with stronger bone structure. Ensure adequate calcium and vitamin D, but do not fear protein.

Hormonal contraceptive (HC) use is associated with a lower likelihood of experiencing menstrual cycle symptoms, specifically uterine cramps, in resistance-trained athletes.

If you are a resistance-trained athlete experiencing severe menstrual cramps, hormonal contraceptives (particularly combined oral pills) are statistically associated with a reduction in these symptoms. However, be aware that nearly half of users report unwanted side effects from the contraceptives themselves. Consult a healthcare provider to weigh the benefit of reduced cramping against the risk of HC side effects.

Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.

Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.

Pre-pregnancy lifestyle interventions (dietary restriction or exercise) initiated at least 9 weeks prior to conception reduce the risk of metabolic-associated fatty liver disease (MAFLD) in offspring of obese mothers, whereas interventions initiated only 1 week prior do not.

If you have obesity and plan to conceive, starting weight management 9+ weeks before trying to get pregnant is critical for your future child's liver health. Standard lifestyle changes may take too long, so discuss pre-pregnancy pharmacotherapy (like GLP-1 agonists) with your doctor to ensure you reach a healthy weight before conception.

Pre-pregnancy use of GLP-1 receptor agonists (e.g., liraglutide) or GLP-1/GIP co-agonists (e.g., tirzepatide) is a promising pharmacotherapeutic strategy for pre-pregnancy weight loss in obese women, potentially mitigating the intergenerational risk of MAFLD in offspring, provided sufficient wash-out periods are observed.

If lifestyle changes aren't enough to help you reach a healthy weight before pregnancy, talk to your doctor about GLP-1 medications. They are effective for weight loss and may improve your future child's liver health. Crucially, you must stop these medications well before trying to conceive to ensure they are out of your system.

Low-load resistance training (50% 1RM) produces greater acute muscle swelling (cellular hydration) than high-load resistance training (85% 1RM) when volume load is equated, primarily due to increased time under tension and training density.

If your goal is to maximize the 'pump' (acute muscle swelling) in a single workout, use lighter weights (around 50% of your max) and perform more reps until you can't do another one. This creates more time under tension and metabolic stress than heavy lifting, which may support muscle growth mechanisms, even though the total weight moved is the same.

A 14-day continuous adaptive infusion of the GLP-1/GCGR co-agonist G3215 produces significant weight loss (mean -2.39 kg) and reduced food intake in adults with overweight or obesity, with adverse effects mitigated by real-time dose adjustment.

This study shows that a 14-day continuous infusion of a specific hormone drug (G3215) can lead to about 2.4 kg of weight loss in adults with overweight or obesity. The drug works by reducing food intake and increasing energy expenditure. Side effects like nausea were common but manageable by adjusting the infusion rate. This approach might offer faster weight loss with better tolerability than current weekly injection options, though it requires wearing a pump for two weeks.

GLP-1 receptor agonists (e.g., semaglutide/Ozempic) suppress appetite and hunger signals by mimicking the hormone GLP-1, leading to significant weight loss but also causing a loss of the sensory and relational pleasure of eating.

GLP-1 drugs like semaglutide work by mimicking a hormone to reduce hunger and increase fullness, leading to weight loss. However, this comes with side effects like nausea and a reduced ability to enjoy food. The paper highlights that while these drugs can help with weight loss, they do not guarantee mental health improvements or self-acceptance, and weight regain is common if treatment stops. They are expensive and often used off-label.